Who is sponsoring NCT02756286?

NCT02756286 is sponsored by Think Now Incorporated.

What drugs are being tested in NCT02756286?

Interventions in NCT02756286: NAT electroencephalography (EEG) test.

What condition does NCT02756286 study?

NCT02756286 studies Attention Deficit Hyperactivity Disorder.

Is NCT02756286 still recruiting?

NCT02756286 is currently completed. Last updated 19 September 2018.

Last reviewed 2018-09-19 · How we verify

NCT02756286: NAT-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

Completed Last updated 19 September 2018

What this trial tests

trial testing NAT electroencephalography (EEG) test in Attention Deficit Hyperactivity Disorder in 258 participants. Completed in 5 July 2018.

Timeline

1 January 2017

Primary endpoint
1 June 2018

5 July 2018

Quick facts

Lead sponsor	Think Now Incorporated
Status	Completed
Study type	OBSERVATIONAL
Enrollment	258
Start date	1 January 2017
Primary completion	1 June 2018
Estimated completion	5 July 2018
Sites	3 locations across United States

Drugs / interventions tested

NAT electroencephalography (EEG) test

Conditions studied

Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →

Sponsor

Think Now Incorporated

Who can join

Adults 18 to 40, any sex, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder

Currently open trials in the same condition.

NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting

Other Think Now Incorporated trials

Trials by the same sponsor.

NCT06256003 — Assessing Mobile Apps for Adult ADHD · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02756286 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Think Now Incorporated
Last refreshed: 19 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02756286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing